Well, kinda scary to me since I paid only a few cents each up to 50
cents back when Greenwich went bust and then it converted 1-for-1 to
BLSI. Still, if this outfit hits only one of their pipeline, it could
really take off. If you didn't already do it, call or write the company
and have them send you the last annual report (it just came out a week
or so ago) and also ask for the press kit: it's easier to read than
the annual and has a good explanation of what they're working on. My
wife used to be a registered nurse and she's pretty leery about stocks,
but she thinks I should hang on to this one even though it's about triple
what we paid. Glad to hear you say it's only money 'cause that means
you understand how speculative these biotech firms are, especially the
small ones like this. The stage three trials for Greenwich's big one -
Therafectin - should be completed around next January. If the FDA says
it's effective and they get approval, the stock will take off like a
rocket. If not, it'll probably dump back, but they have quite a few
promising things they're working on...hope you make a million 'cause
that means I'll make a coupla mil! In case you don't know, Greenwich
had already spent 22 million on Therafectin and ran out of money before
they completed the approval process so that's all free to BLSI and I
think I already mentioned that Zeneca, the British pharmaceutical giant,
took a stake, so they must see something they think looks good. |
